HIV-1 p17 Antibody (17-3): sc-69725

HIV-1 p17 Antibody (17-3) is a mouse monoclonal IgG2b antibody that detects p17 protein of HIV-1 by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Anti-HIV-1 p17 antibody (17-3) specifically targets p17 protein, a crucial structural matrix protein of HIV-1 virus that plays a significant role in viral life cycle. Located in cytoplasm and entering nucleus shortly after viral synthesis, p17 is essential for transport of viral nucleocapsids from nucleus to plasma membrane, where viral assembly occurs. This localization facilitates efficient budding of new virions, thereby contributing to viral spread within host. Additionally, p17 is implicated in HIV-1 pathogenesis, with anti-p17 antibodies serving as serological markers for disease progression, highlighting potential as a target for therapeutic immunizations against HIV-1. HIV-1 p17 monoclonal antibody (17-3) is an invaluable tool for researchers studying HIV-1 biology and developing strategies for intervention.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HIV-1 p17 Antibody (17-3) References:

1. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.  |  Lindenburg, CE., et al. 2002. Vaccine. 20: 2343-7. PMID: 12009290
2. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.  |  Tewari, D., et al. 2003. J Gene Med. 5: 182-9. PMID: 12666184
3. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection.  |  Jiang, JD., et al. 1992. J Acquir Immune Defic Syndr (1988). 5: 382-90. PMID: 1372353
4. Fine epitope specificity of anti-erythropoietin antibodies reveals molecular mimicry with HIV-1 p17 protein: a pathogenetic mechanism for HIV-1-related anemia.  |  Tsiakalos, A., et al. 2011. J Infect Dis. 204: 902-11. PMID: 21849287
5. Flexible and rigid structures in HIV-1 p17 matrix protein monitored by relaxation and amide proton exchange with NMR.  |  Ohori, Y., et al. 2014. Biochim Biophys Acta. 1844: 520-6. PMID: 24373876
6. Effect of Glu12-His89 Interaction on Dynamic Structures in HIV-1 p17 Matrix Protein Elucidated by NMR.  |  Konagaya, Y., et al. 2016. PLoS One. 11: e0167176. PMID: 27907055
7. Identification of a Clade-Specific HLA-C*03:02 CTL Epitope GY9 Derived from the HIV-1 p17 Matrix Protein.  |  Kyobe, S., et al. 2024. Int J Mol Sci. 25: PMID: 39273630
8. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.  |  Sarin, PS., et al. 1995. Cell Mol Biol (Noisy-le-grand). 41: 401-7. PMID: 7580834
9. HIV-1 p17 and IFN-gamma both induce fructose 1,6-bisphosphatase.  |  Besançon, F., et al. 1997. J Interferon Cytokine Res. 17: 461-7. PMID: 9282826
10. Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity.  |  Birk, M., et al. 1998. AIDS. 12: 1973-81. PMID: 9814865

The preferred HIV-1 p17 antibody is HIV-1 p17 Antibody (17-1): sc-69723.